Kaisa
Huhtinen
Senior Researcher, Institute of Biomedicine
Adjunct Professor, Faculty of Medicine
PhD, Adjunct Professor in Cancer Biology
Areas of expertise
Ovarian cancer
personalized medicine
early diagnostics
prediction
prognosis
biomarker
genomics
drug target
interdicipline research;
Biography
2018 Starting as an independent group leader
2016 Adjunct Professor, Cancer Biology, University of Turku
2014 Cell biologist (4 months), Turku University Hospital
2012- Postdoctoral fellow / Senior researcher in Olli Carpén research group, Univ. Turku
2010-2012 Postdoctoral fellow in the ENDOMET study, Prof. Matti Poutanen group, Univ. Turku
2010 Ph.D., Departments of Physiology and Obstetrics & Gynecology, University of Turku
2016 Adjunct Professor, Cancer Biology, University of Turku
2014 Cell biologist (4 months), Turku University Hospital
2012- Postdoctoral fellow / Senior researcher in Olli Carpén research group, Univ. Turku
2010-2012 Postdoctoral fellow in the ENDOMET study, Prof. Matti Poutanen group, Univ. Turku
2010 Ph.D., Departments of Physiology and Obstetrics & Gynecology, University of Turku
Research
I am interested in understanding molecular mechanisms behind high-grade serous ovarian cancer, which is the most lethal type of epithelial ovarian cancer. Our reseach focuses on two main themes: genomic alterations such as gene fusions and development of innovative diagnostic tools. Our ultimate aim is to improve patient survival by 1) developing biomarkers / marker panels for early detection of HGSOC, 2) finding predictive markers enabling personalized therapies, and 3) characterizing new potential drug targets for personalized HGSOC treatment.
Publications
A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer (2021)
Cancers
(A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä)
Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality (2021)
Scientific Reports
(A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä)
Exploratory Analysis of CA125-MGL and –STn Glycoforms in the Differential Diagnostics of Pelvic Masses (2020)
The Journal of Applied Laboratory Medicine
(A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä)
HE4 in the evaluation of tumor load and prognostic stratification of high grade serous ovarian carcinoma (2020)
Acta Oncologica
(A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä)
ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors (2020)
Journal of Pathology
(A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä)
A relational database to identify differentially expressed genes in the endometrium and endometriosis lesions (2020)
Scientific Data
(A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä)
American Association for Cancer Research Special Conference on Advances in Ovarian Cancer Research Sep 13-16, 2019 Atlanta, GA, USA Abstracts (2020)
Clinical Cancer Research
(O2 Muu)
RNA-seq analysis of high-grade serous ovarian cancer patients before and after chemotherapy reveals chemoresistance-associated genes and pathways (2020)
Clinical Cancer Research
(O2 Muu)
A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer (2020)
Gynecologic Oncology
(A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä)
Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy (2020)
Cancer Discovery
(A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä)